[{"address1": "100 Overlook Center", "address2": "Suite 102", "city": "Princeton", "state": "NJ", "zip": "08540", "country": "United States", "phone": "609 375 2227", "website": "https://www.sonnetbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Pankaj  Mohan Ph.D.", "age": 58, "title": "Founder, Chairman, CEO & President", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 926996, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John K. Cini Ph.D.", "age": 70, "title": "Chief Scientific Officer & Co-Founder", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 602480, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jay  Cross", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 603420, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Donald J. Griffith CPA, CPA", "age": 74, "title": "Controller & Director", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 134048, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Dexter", "age": 68, "title": "Chief Technical Officer", "yearBorn": 1955, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard T. Kenney FACP, M.D.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Manuel  Dafonseca", "title": "Head of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.875, "open": 0.9, "dayLow": 0.835, "dayHigh": 0.9, "regularMarketPreviousClose": 0.875, "regularMarketOpen": 0.9, "regularMarketDayLow": 0.835, "regularMarketDayHigh": 0.9, "beta": 0.989, "trailingPE": 0.298968, "forwardPE": -0.333373, "volume": 49935, "regularMarketVolume": 49935, "averageVolume": 37788, "averageVolume10days": 47240, "averageDailyVolume10Day": 47240, "bid": 0.8002, "ask": 0.8872, "bidSize": 100, "askSize": 100, "marketCap": 4384062, "fiftyTwoWeekLow": 0.83, "fiftyTwoWeekHigh": 10.12, "priceToSalesTrailing12Months": 47.2772, "fiftyDayAverage": 1.5028, "twoHundredDayAverage": 1.6975, "currency": "USD", "enterpriseValue": -1002516, "floatShares": 2750647, "sharesOutstanding": 5218500, "sharesShort": 338631, "sharesShortPriorMonth": 408353, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.1088, "heldPercentInsiders": 0.09093001, "heldPercentInstitutions": 0.025969999, "shortRatio": 12.2, "shortPercentOfFloat": 0.111899994, "impliedSharesOutstanding": 5465730, "bookValue": 0.981, "priceToBook": 0.85637105, "lastFiscalYearEnd": 1696032000, "nextFiscalYearEnd": 1727654400, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -8426565, "trailingEps": 2.81, "forwardEps": -2.52, "lastSplitFactor": "1:22", "lastSplitDate": 1693526400, "enterpriseToRevenue": -10.811, "enterpriseToEbitda": 0.079, "52WeekChange": -0.91515154, "SandP52WeekChange": 0.24919295, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "SONN", "underlyingSymbol": "SONN", "shortName": "Sonnet BioTherapeutics Holdings", "longName": "Sonnet BioTherapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1162305000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e0f4f091-b896-3bb3-bb50-c62febf22cab", "messageBoardId": "finmb_410378138", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.8401, "targetHighPrice": 44.0, "targetLowPrice": 7.0, "targetMeanPrice": 27.0, "targetMedianPrice": 30.0, "recommendationMean": 1.3, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 3, "totalCash": 3786184, "totalCashPerShare": 1.216, "ebitda": -12650042, "totalDebt": 168939, "quickRatio": 1.506, "currentRatio": 1.889, "totalRevenue": 92731, "debtToEquity": 5.531, "revenuePerShare": 0.032, "returnOnAssets": -0.82351995, "returnOnEquity": -2.00086, "freeCashflow": -12606992, "operatingCashflow": -13099083, "operatingMargins": -136.55505, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-11"}]